← Leaderboards
Shyam Sharan
Basic Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Basic Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMutationTumorMutantMouse ModelBrca2 GeneCellsAllelesBrca1 GeneBaseEngineeringResponseMalignant Breast NeoplasmGenesGeneticEvaluationLaboratoriesCollaborationsPre-ClinicalTissuesEmbryonic Stem CellAnimalsProteinsVariant
Grant awards (118)
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,770,891
ZIA · FY2025 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,770,891
ZIA · FY2025 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,475,743
ZIA · FY2025 · CA · contact PI
Identification of genetic interactors of BRCA2$1,110,885
ZIA · FY2025 · CA · contact PI
Functional Evaluation of BRCA2 Variants on Tumorigenesis$740,589
ZIA · FY2025 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$617,157
ZIA · FY2025 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$295,148
ZIA · FY2025 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$295,148
ZIA · FY2025 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$295,148
ZIG · FY2025 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$2,041,466
ZIA · FY2024 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$2,041,466
ZIA · FY2024 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,701,222
ZIA · FY2024 · CA · contact PI
Identification of genetic interactors of Brca2$1,421,526
ZIA · FY2024 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$947,684
ZIA · FY2024 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$789,736
ZIA · FY2024 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$340,244
ZIA · FY2024 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$340,244
ZIA · FY2024 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$340,244
ZIG · FY2024 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,286,039
ZIA · FY2023 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,286,039
ZIA · FY2023 · CA · contact PI
Identification of genetic interactors of Brca2$1,190,140
ZIA · FY2023 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,071,699
ZIA · FY2023 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$793,427
ZIA · FY2023 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$661,190
ZIA · FY2023 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$214,340
ZIA · FY2023 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$214,340
ZIA · FY2023 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$214,340
ZIG · FY2023 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,384,924
ZIA · FY2022 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,384,924
ZIA · FY2022 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,154,104
ZIA · FY2022 · CA · contact PI
Identification of genetic interactors of Brca2$1,091,687
ZIA · FY2022 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$727,791
ZIA · FY2022 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$606,493
ZIA · FY2022 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$230,821
ZIG · FY2022 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$230,821
ZIA · FY2022 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$230,821
ZIA · FY2022 · CA · contact PI
Identification of genetic interactors of Brca2$1,064,216
ZIA · FY2021 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$986,350
ZIA · FY2021 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$986,350
ZIA · FY2021 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$821,958
ZIA · FY2021 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$709,478
ZIA · FY2021 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$591,231
ZIA · FY2021 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$164,392
ZIG · FY2021 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$164,392
ZIA · FY2021 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$164,392
ZIA · FY2021 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,327,446
ZIA · FY2020 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,327,446
ZIA · FY2020 · CA · contact PI
Identification of genetic interactors of Brca2$1,165,540
ZIA · FY2020 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,106,205
ZIA · FY2020 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$777,026
ZIA · FY2020 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$647,522
ZIA · FY2020 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$221,242
ZIA · FY2020 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$221,242
ZIA · FY2020 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$221,242
ZIG · FY2020 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,794,070
ZIA · FY2019 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEM-GDA models$1,495,060
ZIA · FY2019 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,495,060
ZIA · FY2019 · CA · contact PI
Identification of genetic interactors of Brca2$1,205,586
ZIA · FY2019 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$803,724
ZIA · FY2019 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$669,770
ZIA · FY2019 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$598,023
ZIG · FY2019 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$418,616
ZIA · FY2019 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$179,407
ZIA · FY2019 · CA · contact PI
Development and Preclinical Applications of Pancreatic Adenocarcinoma Models$1,588,248
ZIA · FY2018 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEMGDA models$1,323,540
ZIA · FY2018 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,323,540
ZIA · FY2018 · CA · contact PI
Identification of genetic interactors of Brca2$1,039,510
ZIA · FY2018 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$693,007
ZIA · FY2018 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$577,506
ZIA · FY2018 · CA · contact PI
Development of Novel Informative Preclinical Animal Models - CAPR Infrastructure$529,416
ZIG · FY2018 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$370,592
ZIA · FY2018 · CA · contact PI
Preclinical Modelling and Therapeutic Development for Other Cancer Indications$158,825
ZIA · FY2018 · CA · contact PI
Development and Preclinical Application of Pancreatic Adenocarcinoma Models$1,539,864
ZIA · FY2017 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,283,220
ZIA · FY2017 · CA · contact PI
Therapeutic evaluation in ovarian and breast cancer GEMGDA models$1,283,220
ZIA · FY2017 · CA · contact PI
Identification of genetic interactors of Brca2$1,029,736
ZIA · FY2017 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$686,490
ZIA · FY2017 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$572,076
ZIA · FY2017 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$513,288
ZIA · FY2017 · CA · contact PI
Development of Novel Preclinical Animal Models - CAPR Infrastructure$513,288
ZIG · FY2017 · CA · contact PI
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma$1,237,901
ZIA · FY2016 · CA · contact PI
Development of Novel Preclinical Animal Models - CAPR Infrastructure$1,237,901
ZIG · FY2016 · CA · contact PI
Development and Preclinical Application of Pancreatic Adenocarcinoma Models$990,320
ZIA · FY2016 · CA · contact PI
Preclinical Development of Therapeutics in Murine Models of Lung Cancer$990,320
ZIA · FY2016 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$966,864
ZIA · FY2016 · CA · contact PI
Identification of genetic interactors of Brca2$725,148
ZIA · FY2016 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$725,148
ZIA · FY2016 · CA · contact PI
Validation of, and therapeutic evaluation in ovarian cancer GEM models$495,160
ZIA · FY2016 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$906,612
ZIA · FY2015 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$906,612
ZIA · FY2015 · CA · contact PI
Identification of genetic interactors of Brca2$453,306
ZIA · FY2015 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$738,735
ZIA · FY2014 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$738,735
ZIA · FY2014 · CA · contact PI
Identification of genetic interactors of Brca2$369,367
ZIA · FY2014 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$647,584
ZIA · FY2013 · CA · contact PI
Functional Analysis of Human Breast Cancer Susceptibility Gene Variants$647,584
ZIA · FY2013 · CA · contact PI
Identification of genetic interactors of Brca2$323,792
ZIA · FY2013 · CA · contact PI
Functional Analysis of Variants Identified in Human Breast Cancer Susceptibility$659,502
ZIA · FY2012 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$659,502
ZIA · FY2012 · CA · contact PI
Identification of genetic interactors of Brca2$329,752
ZIA · FY2012 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$719,226
ZIA · FY2011 · CA · contact PI
Functional Analysis of Variants Identified in Human Breast Cancer Susceptibility$719,226
ZIA · FY2011 · CA · contact PI
Identification of genetic interactors of Brca2$359,613
ZIA · FY2011 · CA · contact PI
Functional Analysis of Variants Identified in Human Breast Cancer Susceptibility$615,411
ZIA · FY2010 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$615,411
ZIA · FY2010 · CA · contact PI
Identification of genetic interactors of Brca2$307,705
ZIA · FY2010 · CA · contact PI
Functional Analysis of Variants Identified in Human Breast Cancer Susceptibility$628,174
ZIA · FY2009 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$628,174
ZIA · FY2009 · CA · contact PI
Examining the Role of Rad51c as a Tumor Suppressor$314,087
ZIA · FY2009 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$1,399,315
Z01 · FY2008 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Genes in Mice$1,625,703
Z01 · FY2007 · CA · contact PI
Functional Analysis of Breast Cancer Susceptibility Gene$0
Z01 · FY2006 · BC · contact PI
Functional Analysis of Breast Cancer Susceptibility Gene$0
Z01 · FY2005 · BC
Functional Analysis of Breast Cancer Susceptibility Gene$0
Z01 · FY2004 · BC
Functional Analysis of Breast Cancer Susceptibility Gene$0
Z01 · FY2003 · BC
Functional Analysis of Breast Cancer Susceptibility Gene$0
Z01 · FY2002 · BC
Functional Analysis--Breast Cancer Susceptibility Genes$0
Z01 · FY2001 · BC
FUNCTIONAL ANALYSIS OF BREAST CANCER SUSCEPTIBILITY GENE$0
Z01 · FY2000 · BC